Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

American Journal of Hematology - United States
doi 10.1002/ajh.25238
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Leukemia Research
Cancer ResearchOncologyHematology
2013English

Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin, and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Cancer
Cancer ResearchOncology
2018English

Transplant Conditioning With Treosulfan/Fludarabine With or Without TBI. A Randomized Phase II Trial in Patients With MDS and AML

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Annals of Oncology
MedicineOncologyHematology
2017English

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Advanced Intermediate-Grade or High-Grade Liposarcoma

Cancer
Cancer ResearchOncology
2017English

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

A Phase I Study of Intravenous Liposomal Daunorubicin (DaunoXome) in Paediatric Patients With Relapsed or Resistant Solid Tumours

British Journal of Cancer
Cancer ResearchOncology
2006English

Intesive Fludarabine-High Dose Cytarabine-Idarubicin Combination as Induction Therapy With Risk-Adapted Consolidation May Improve Treatment Efficacy in Younger Acute Myeloid Leukemia (AML) Patients: Rationales, Evidences and Future Perspectives

BioScience Trends
BiochemistryHealthMedicineGeneticsMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy